<DOC>
	<DOCNO>NCT00597480</DOCNO>
	<brief_summary>Recombinant growth hormone ( rhGH ) treatment widely use France normalize height childhood final height child bear small gestational age ( SGA ) . Because rhGH associate increased insulin level insulin resistance , concern express regard late consequence rhGH treatment risk factor diabetes mellitus type II metabolic syndrome , especially possibly predisposed subject SGA child .</brief_summary>
	<brief_title>Study Growth-promoting Metabolic Effects Growth Hormone ( rhGH )</brief_title>
	<detailed_description>Recombinant growth hormone ( rhGH ) treatment widely use France normalize height childhood final height child bear small gestational age ( SGA ) . Because rhGH associate increased insulin level insulin resistance , concern express regard late consequence rhGH treatment risk factor diabetes mellitus type II metabolic syndrome , especially possibly predisposed subject SGA child . Because rhGH use population sharply increase come year , purpose identify analyze factor predispose child bear SGA metabolic consequence rhGH therapy . The main objective study identify analyze factor implicate variability metabolic growth response rhGH treatment child bear SGA . We want : - Quantify metabolic effect rhGH treatment analyze insulin level , insulin sensitivity lipid profile ( lipolysis ketogenesis ) ; - Evaluate effect two different rhGH regimens growth child bear SGA ; - Determine metabolic effect rhGH therapy correlate growth responses two group ; - Identify factor , especially genetic factor , responsible variation individual metabolic growth-promoting effect rhGH child bear SGA . This randomized , open-labeled , 2-year study , compare two regimen rhGH therapy growth responses metabolic effect short child bear SGA . 100 prepubertal , non GH deficient , short child ( height &lt; -3 SDS ) bear SGA ( birth height &lt; -2 SDS ) randomize receive either recommend dose EU rhGH ( Norditropine SimpleXxÂ® ) , dose achieve `` treat-to target '' value IGF-1 level within +1.5 +2.5 SDS interval ( start dose , 0.067 mg/kg/day ) 24 month . Metabolic effect rhGH treatment evaluate body mass index ( BMI ) , fast insulin glucose level , HOMA index insulin resistance , insulin glucose level OGTT , HbA1C fast serum lipid ( free fatty acid , 3-hydroxybutyrate , total cholesterol , LDL HDL cholesterol , triglyceride ) . Height , growth velocity , IGF-1 IGF-BP3 level evaluate growth response rhGH treatment . Polymorphisms different gene signal pathway GH insulin analyze order search possibly responsible variability metabolic growth response rhGH treatment SGA child .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<criteria>Prepubertal age Prepubertal characteristic Non GH deficient Short child ( height &lt; 2.5 SDS ) Born SGA ( birth height &lt; 2 SDS ) Parental height adjust ( &lt; 1 DS ) No rhGH treatment inclusion ALLERY rhGH excipients Small height etiology Cancer cancer treatment ongoing Drugs interference growth Mental impairment Hypertrophic cardiopathy impairment Hypertension control Intra cranial hypertension control Diabetes hyperglycaemia without diabetes Dyslipidemia Hepatitis Kidney failure Chromosomic aberration and/or genetic disorder ( except Silver Russel Syndrome ) No social security State health bad condition cardiac surgery , polytraumatism</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>Child</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>metabolic syndrome X</keyword>
	<keyword>child bear small gestational age</keyword>
</DOC>